以下是知识库中与该主题相关的实验方案、常见问题、指南与技术文章。
KRAS G12D is an important driver mutation in solid tumors such as pancreatic, colorectal, and lung cancers. The emergence of molecules such as MRTX1133 has demonstrated that KRAS G12D can be directly targeted pharmacologically, whereas targeted protein degradation technologies such as PROTACs ...
KRAS G12D是胰腺癌、结直肠癌和肺癌等实体瘤中的重要驱动突变。MRTX1133等分子的出现证明了KRAS G12D可以被直接药理干预，而PROTAC等靶向蛋白降解技术进一步将作用模式从“占据并抑制KRAS”推进到“募集E3连接酶并清除KRAS蛋白”。
In the field of cancer research, the KRAS gene has always occupied an important and unique position. For many years, due to its complex structure and functional characteristics, KRAS has been regarded as an "undruggable" target.
在癌症研究领域，KRAS基因一直占据着重要且特殊的地位。多年来，由于其复杂的结构和功能特性，KRAS被视为 “不可成药” 靶点，然而随着科研技术的不断进步，针对KRAS的靶向治疗取得了突破性进展。
同一批资源中共同出现的其他主题。
危险品化学品经营许可证（带存储）